New Releases from NCBI BookshelfUpadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. Upadacitinib can be used with or without topical corticosteroids [Internet].Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. Upadacitinib can be used with or without topical corticosteroids [Internet].
CADTH recommends that Rinvoq be reimbursed by public drug plans for the treatment of adults and adolescents 12 years of […]
